Vancouver, British Columbia--(Newsfile Corp. - January 12, 2018)
-
Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB:
ATTBF) (the "Company" or "Abattis") is pleased to announce that,
along with Northern Vine Labs, it will be attending the Lift
Cannabis Expo, Canada's largest and best-attended cannabis
tradeshow, from January 12 to 14 at the Vancouver Convention
Centre. This year's Lift Expo will feature nearly 200 exhibitors
from across North America and will host talks by cannabis thought
leaders, live cooking and growing demos, a vape lounge and a
cannabis career fair. For more information about the Lift Expo, see
www.liftexpo.ca. Northern Vine
Labs is a subsidiary of Abattis and Emerald Health Therapeutics
Inc.
Dr. David Galvez, Abattis's senior scientific advisor and a
seasoned expert on the formulation and commercialization of
botanical-based products, will be participating on the Lift Expo
panel on "Ancillary Services in the Cannabis Space: Overlooked
Opportunities and Next Steps" and Abattis will be manning a booth
at the Lift Expo. We welcome shareholders and attendees to come by
and chat with us.
Abattis also announces that, further to its news release dated
December 12, 2017, it is anticipated that Frank Zhu will be engaged
as technology advisor to Abattis. Mr. Zhu has been instrumental in
the development of Abattis's column chromatography extraction
technology, which is capable of extraction on an industrial scale,
delivers significant cost advantages, separates cannabinoids on a
molecular level and extracts pure isolates such as CBD and THCA
while separating pesticides from biomass. We look forward to
working more closely with Mr. Zhu, as the industry tends towards a
commoditization of marijuana and hemp and downstream services such
as extraction become an increasingly important focus.
Abattis also announces the resignation of Dr. Shuang Xie as
chief technology officer and a director of the Company. We thank
Dr. Xie for her contributions to the Company and wish her all the
best in her future endeavours.
About Abattis Bioceuticals Corp.
Abattis is a life sciences and biotechnology company which
aggregates, integrates, and invests in cannabis technologies and
biotechnology services for the legal cannabis industry developing
in Canada. The Company has successfully developed and licensed
natural health products, medicines, extractions, and ingredients
for the biologics, nutraceutical, bioceutical, and cosmetic
markets. The Company is also seeking to acquire exclusive
intellectual property rights to agricultural technologies to be
employed in extraction and processing of botanical ingredients and
compounds. The Company follows strict standard operating protocols,
and adheres to the applicable laws of Canada and foreign
jurisdictions.
ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP,
"Rob Abenante"
Robert Abenante, President & CEO
For more information, please visit the Company's website at:
www.abattis.com or
www.northernvinelabs.com
For inquiries, please contact the Company at (604) 336-0881 or
at
[email protected]
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use
of any of the words "anticipate", "continue", "estimate", "expect",
"may", "will", "project", "intends", "should", "believe" and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements in this press release
include statements regarding: the benefits of Abattis's column
chromatography extraction technology and Mr. Zhu's engagement by
the Company. Although the Company believes that the expectations
and assumptions on which the forward-looking statements are based
are reasonable, undue reliance should not be placed on the
forward-looking statements because the Company can give no
assurance that they will prove to be correct. Since forward-looking
statements address future events and conditions, by their very
nature they involve inherent risks and uncertainties, including:
that the development Abattis's column chromatography extraction
technology will not progress as expected; that Mr. Zhu will not be
engaged by the Company or that such engagement will not benefit the
Company as expected; that the Company will not be able to execute
its proposed business plan in the time required or at all due to
regulatory, financial or other issues; that the Company's
competitors may develop competing technologies; changes in
regulatory requirements; and other factors beyond the Company's
control. Additional risk factors are included in the Company's
Management's Discussion and Analysis, available under the Company's
profile on
www.sedar.com. The
forward-looking statements are made as at the date hereof and the
Company disclaims any intent or obligation to publicly update any
forward-looking statements, where because of new information,
future events or results, or otherwise, except as required by
applicable securities laws.

© Newsfile Corp, source Press Releases